Kirchgraber Paul R
SEC CIK 1791393 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| LH | Labcorp | CEO, Covance Drug Development | 17.2K | — | $2.94M | 24 | 2021-11-01 | 2023-05-19 |
Most active insiders at LH, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Schechter Adam H | Pres, CEO, Dir | — | $8.44M |
| 2 | Parham Richelle P | Dir | — | $1.78M |
| 3 | Wilkinson Peter J | SVP, CAO | — | $1.06M |
| 4 | ANDERSON KERRII B | Dir | — | $954.1K |
| 5 | Caveney Brian J | EVP, CMO, CSO, Pres of ED | — | $429.5K |
| 6 | Meltzer Jonathan C | EVP, Ops | — | $298.8K |
| 7 | Summy Amy B. | EVP, CMO | — | $283.4K |
| 8 | Kyle Kathryn W | EVP, CLO | — | $227.4K |
| 9 | van der Vaart Sandra D | EVP, Corp. Affairs | — | $156.0K |
| 10 | Vaughn Bryan T | EVP, Pres, Diagnostics | — | $67.0K |
Kirchgraber Paul R made no open-market trades at LH in the last 12 months.
Transactions 24
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-23 | 2023-05-19 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | $182.51 | +4,300 | 17.2K | +33% | +$784.8K |
| D | 2023-05-23 | 2023-05-19 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | S - Sale+OE | $216.91 | -4,300 | 12.9K | -25% | -$932.7K |
| 2023-04-03 | 2023-03-30 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $224.70 | -2,886 | 12.9K | -18% | -$648.5K | |
| 2023-04-03 | 2023-03-30 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | A - Grant | $0.00 | +6,763 | 15.8K | +75% | $0 | |
| D | 2023-02-23 | 2023-02-21 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | S - Sale+OE | $250.58 | -8,000 | 9,069 | -47% | -$2.00M |
| D | 2023-02-23 | 2023-02-21 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | $182.51 | +3,000 | 17.1K | +21% | +$547.5K |
| D | 2023-02-14 | 2023-02-11 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +483 | 14.2K | +4% | — |
| D | 2023-02-14 | 2023-02-13 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $248.13 | -142 | 14.1K | -1.0% | -$35.2K |
| D | 2023-02-07 | 2023-02-06 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $244.50 | -164 | 13.7K | -1% | -$40.1K |
| D | 2023-02-07 | 2023-02-04 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +560 | 13.9K | +4% | — |
| D | 2023-02-06 | 2023-02-02 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $254.99 | -141 | 13.3K | -1% | -$36.0K |
| D | 2023-02-06 | 2023-02-02 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +443 | 13.5K | +3% | — |
| D | 2022-11-03 | 2022-11-01 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $222.56 | -892 | 13.0K | -6% | -$198.5K |
| D | 2022-11-03 | 2022-11-01 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +2,007 | 13.9K | +17% | — |
| 2022-03-29 | 2022-03-28 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $276.42 | -1,648 | 11.9K | -12% | -$455.5K | |
| 2022-03-29 | 2022-03-27 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | A - Grant | $0.00 | +3,707 | 13.6K | +38% | $0 | |
| D | 2022-02-15 | 2022-02-14 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $272.68 | -108 | 9,856 | -1% | -$29.4K |
| D | 2022-02-15 | 2022-02-12 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +317 | 9,964 | +3% | — |
| D | 2022-02-08 | 2022-02-04 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $277.48 | -165 | 9,647 | -2% | -$45.8K |
| D | 2022-02-08 | 2022-02-04 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +560 | 9,812 | +6% | — |
| D | 2022-02-04 | 2022-02-02 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +443 | 9,396 | +5% | — |
| D | 2022-02-04 | 2022-02-02 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $273.18 | -144 | 9,252 | -2% | -$39.3K |
| D | 2021-11-03 | 2021-11-01 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $288.78 | -898 | 8,953 | -9% | -$259.3K |
| D | 2021-11-03 | 2021-11-01 | LH | Labcorp | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +2,007 | 9,851 | +26% | — |
Purchase Sale Sale after option exercise All abbreviations